SCHEMBL7909251

SCHEMBL7909251

C[C@H](NC(=O)C1(c2ccc(F)cn2)CCN(C(=O)c2ccc(-c3ccc(F)cc3)cc2)CC1)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.44
SLC6A7 Q99884 2/20 0.42
ROCK2 O75116 1/20 0.40
AKT1 P31749 1/20 0.40
AKT2 P31751 1/20 0.40
KCNH2 Q12809 1/20 0.40
AKT3 Q9Y243 1/20 0.40
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.39
ACACB O00763 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
PRKAA2 P54646 1/20 0.39
PTPN1 P18031 1/20 0.39
HTR2B P41595 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7910239 0.89 TACR3 (0.39) KITALDH1A1LMNAMEN1KMT2A
SCHEMBL7910840 0.88 TACR3 (0.38) KITROCK2AKT1AKT2KCNH2
SCHEMBL13092254 0.86 KIT (0.44) KITSLC6A7MAPTPOLBALDH1A1
SCHEMBL378834 0.83 TACR1 (0.48) KITSLC6A7POLBMEN1KMT2A
SCHEMBL13092321 0.82 KCNH2 (0.43) KITSLC6A7KCNH2
SCHEMBL3103856 0.81 SLC6A7 (0.50) SLC6A7PRKAA2PTPN1HTR2BMEN1
SCHEMBL3714839 0.81 NPC1 (0.49) SLC6A7POLBMEN1KMT2ACYP3A4
SCHEMBL7900592 0.79 NPY1R (0.45) SLC6A7KCNH2ALDH1A1MEN1KMT2A
SCHEMBL13092320 0.78 POLB (0.47) KITSLC6A7MAPTPOLBALDH1A1
SCHEMBL3104194 0.77 OPRM1 (0.48) SLC6A7MAPTPOLBHRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 KIT 865/4885SLC6A7 105/4885ROCK2 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.